• Abbott Laboratories (NYSE:ABT) announced a pending US$21b acquisition of Exact Sciences.
• The deal marks a major move into cancer diagnostics for Abbott.
• The acquisition comes as Abbott reports underperformance in its nutrition segment and weaker sales growth.
• Management has publicly acknowledged operational pressures, including increasing production costs.

Abbott Laboratories, best known for its diversified healthcare portfolio across diagnostics, medical devices, nutrition and established pharmaceuticals, is now moving deeper into cancer testing through the planned purchase of Exact Sciences. Cancer diagnostics is a key focus area for many large healthcare companies as screening technologies, personalized medicine and demographic trends keep demand in focus for investors.

This transaction arrives at a time when Abbott is contending with softer results in its nutrition business, higher production expenses and less robust sales growth across parts of the portfolio. For investors, the acquisition and management’s stated intent to adjust the business mix could become an important factor in how the risk and opportunity profile of NYSE:ABT evolves over time.

Stay updated on the most important news stories for Abbott Laboratories by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Abbott Laboratories.

Quick Assessment

• ✅ Price vs Analyst Target: At US$106.09, the share price is about 22% below the US$136.32 analyst target range midpoint.
• ❌ Simply Wall St Valuation: Shares are flagged as trading about 14% above estimated fair value.
• ❌ Recent Momentum: The stock has delivered a 15.7% decline over the last 30 days.

Check out Simply Wall St's in depth valuation analysis for Abbott Laboratories.

Key Considerations

• 📊 The US$21b Exact Sciences deal shifts more weight toward cancer diagnostics, while the nutrition segment and cost pressures remain key watchpoints.
• 📊 Keep an eye on margins, the 28.3x P/E versus the 31.1x Medical Equipment average, and how acquisition synergies and integration expenses flow through future earnings.
• ⚠️ Net profit margin has moved from 31.8% to 14.7%, so any further pressure from deal financing or integration issues would be important for you to monitor.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Abbott Laboratories analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.